Vor Biopharma (NASDAQ:VOR) Trading Up 10% – Should You Buy?

Vor Biopharma Inc. (NASDAQ:VOR) was up 10% during trading on Thursday . The company traded as high as $14.17 and last traded at $14.3010. Approximately 622,068 shares changed hands during mid-day trading, a decline of 35% from the average daily volume of 959,875 shares. The stock had previously closed at $13.00.

Analyst Upgrades and Downgrades

Several analysts have commented on VOR shares. HC Wainwright reissued a “buy” rating and issued a $31.00 target price on shares of Vor Biopharma in a report on Monday, May 18th. Jefferies Financial Group upgraded Vor Biopharma to a “strong-buy” rating in a research note on Thursday, April 30th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Vor Biopharma in a research report on Monday, June 1st. Wells Fargo & Company initiated coverage on Vor Biopharma in a research report on Thursday, March 19th. They set an “overweight” rating and a $30.00 price objective on the stock. Finally, Wedbush increased their price objective on Vor Biopharma from $15.00 to $18.00 and gave the company a “neutral” rating in a research report on Thursday, May 14th. Two research analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Vor Biopharma presently has a consensus rating of “Moderate Buy” and a consensus price target of $42.25.

Vor Biopharma Trading Up 1.9%

The firm has a 50-day moving average of $15.09 and a 200 day moving average of $13.90.

Vor Biopharma (NASDAQ:VOR) last released its quarterly earnings data on Monday, March 30th. The company reported $307.61 EPS for the quarter. As a group, research analysts predict that Vor Biopharma Inc. will post -2.51 EPS for the current fiscal year.

Insider Activity at Vor Biopharma

In related news, Director Ra Capital Management, L.P. sold 165,150 shares of the stock in a transaction on Wednesday, April 22nd. The stock was sold at an average price of $15.77, for a total transaction of $2,604,415.50. Following the sale, the director directly owned 2,402,095 shares of the company’s stock, valued at $37,881,038.15. This trade represents a 6.43% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Insiders sold 3,002,903 shares of company stock worth $49,412,176 over the last 90 days. Company insiders own 0.27% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of VOR. RA Capital Management L.P. boosted its position in Vor Biopharma by 172.7% in the fourth quarter. RA Capital Management L.P. now owns 5,404,998 shares of the company’s stock worth $70,697,000 after purchasing an additional 3,422,697 shares during the last quarter. Fcpm Iii Services B.V. boosted its position in Vor Biopharma by 852.8% in the fourth quarter. Fcpm Iii Services B.V. now owns 3,617,354 shares of the company’s stock worth $47,315,000 after purchasing an additional 3,237,714 shares during the last quarter. Frazier Life Sciences Management L.P. purchased a new position in Vor Biopharma in the fourth quarter worth about $33,275,000. Paradigm Biocapital Advisors LP purchased a new position in Vor Biopharma in the fourth quarter worth about $22,890,000. Finally, NEXTBio Capital Management LP purchased a new position in Vor Biopharma in the fourth quarter worth about $13,080,000. 97.29% of the stock is owned by hedge funds and other institutional investors.

About Vor Biopharma

Vor Biopharma, Inc is a clinical-stage biotechnology company focused on the development of next-generation, allogeneic cell therapies for patients with hematologic malignancies. The company’s proprietary platform leverages genome editing to engineer donor-derived hematopoietic stem cells (HSCs), enabling the generation of off-the-shelf therapeutic candidates designed to overcome limitations of traditional autologous and matched donor transplants. By targeting key surface antigens and reconstituting the patient’s immune system, Vor aims to deliver curative potential with reduced treatment timelines and broader patient applicability.

The lead program, VOR33, is a CD33-edited HSC product candidate being evaluated in relapsed or refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS).